Market capitalization | $36.37m |
Enterprise Value | $31.31m |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.03 |
P/S ratio (TTM) P/S ratio | 1.19 |
P/B ratio (TTM) P/B ratio | 7.08 |
Revenue growth (TTM) Revenue growth | 61.47% |
Revenue (TTM) Revenue | $30.47m |
EBIT (operating result TTM) EBIT | $454.00k |
As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.
Mar '25 |
+/-
%
|
||
Revenue | 30 30 |
61%
61%
|
|
Gross Profit | 27 27 |
64%
64%
|
|
EBITDA | 0.49 0.49 |
113%
113%
|
EBIT (Operating Income) EBIT | 0.45 0.45 |
112%
112%
|
Net Profit | -0.65 -0.65 |
88%
88%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
InnoCan Pharma Corp. operates as a pharmaceutical tech company. Its segments include: Pharmaceuticals and Consumer Wellness. The Pharmaceuticals segment focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science. It involves two drug delivery technologies: LPT CBD- loaded liposome platform and CLX CBD-loaded exosomes platform. The Consumer Wellness segment develops and markets a wide portfolio of innovative and self-care products to promote a healthier lifestyle. The company was founded in October 2017 and is headquartered in Alberta, Canada.
Head office | Canada |
CEO | Iris Bincovich |
Founded | 2018 |
Website | innocanpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.